Agonistic anti-PDGFRa autoantibodies are enriched in SSc sera and recognize specific conformational epitopes, that can be used to discriminate agonistic from nonagonistic antibodies and block PDGFRa signaling in SSc. PubMed, Arthritis Rheumatol, 03/25/2015. (Also see Autoantibodies)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.